US · PGEN · BIOTECHNOLOGY
Precigen, Inc. (PGEN) intrinsic value and stock valuation
$4.21as of 2026-11-21 · Mkt cap 2.46B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Precigen, Inc. DCF and intrinsic value
InvestorsCraft values PGEN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PGEN’s statements →
Precigen, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.68M | $3.92M | $6.22M | $26.9M | $14.3M |
| Operating income | -$-106.6M | -$-135.03M | -$-99.76M | -$-75.73M | -$-91.95M |
| Net income | -$-250.64M | -$-126.23M | -$-95.9M | $28.3M | -$-92.17M |
| EPSd | -$-822.55K | -$-471.48K | -$-392.16K | $141.3K | -$-466.07K |
| Operating cash flow | -$-87.83M | -$-68.17M | -$-66.93M | -$-65.05M | -$-55.77M |
| Capital expenditure | -$-2M | -$-8.58M | -$-1.54M | -$-4.92M | -$-7.25M |
| Free cash flow | -$-89.83M | -$-76.76M | -$-68.47M | -$-69.97M | -$-63.02M |
| Total assets | $156.6M | $145.3M | $151M | $216M | $359.9M |
| Total debt | $98.3M | $5.5M | $7.1M | $51.4M | $190.1M |
| Net debt | $68.1M | -$-24.02M | -$-480K | $46.6M | $153.7M |
| Total equity | $20.9M | $38.5M | $118.5M | $126.3M | $107.4M |
| Cash and short-term investments | $97.9M | $97.9M | $62.9M | $56M | $108.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.68M | $3.92M | $6.22M | $26.9M | $14.3M |
| Cost of revenue | $6.1M | $4.27M | $6.12M | $6.34M | $53.7M |
| Gross profit | $3.59M | -$-340K | $110K | $20.6M | -$-39.41M |
| Research and development expenses | $40.1M | $53.1M | $48.6M | $47.2M | $47.9M |
| Selling, general and administrative expenses | $70.1M | $41.3M | $40.4M | $48M | $0.00 |
| Other expenses | $0.00 | $40.3M | $10.8M | $1.12M | $4.6M |
| Operating expenses | $110.2M | $134.7M | $99.9M | $96.3M | $52.5M |
| Cost and expenses | $116.3M | $139M | $106M | $102.6M | $106.2M |
| Interest income | $3.21M | $1.42M | $3.24M | $130K | $170K |
| Interest expense | $3.87M | $10K | $470K | $6.77M | $18.8M |
| Depreciation and amortization | $3.2M | $4.53M | $6.67M | $10.8M | $13.8M |
| Ebitda | -$-243.57M | -$-123.5M | -$-89.23M | -$-62.43M | -$-77.64M |
| Operating income | -$-106.6M | -$-135.03M | -$-99.76M | -$-75.73M | -$-91.95M |
| Total other income/expenses, net | -$-144.04M | $7M | $3.4M | -$-4.24M | -$-19.02M |
| Income before tax | -$-250.64M | -$-128.03M | -$-96.36M | -$-79.97M | -$-110.97M |
| Income tax expense | $0.00 | -$-1.79M | -$-460K | -$-190K | -$-160K |
| Net income | -$-250.64M | -$-126.23M | -$-95.9M | $28.3M | -$-92.17M |
| Weighted average shares outstanding | $304.7M | $267.7M | $244.5M | $200.4M | $197.8M |
| Weighted average diluted shares outstanding | $304.7M | $267.7M | $244.5M | $200.4M | $197.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $97.9M | $97.9M | $62.9M | $56M | $108.7M |
| Net receivables | $4.36M | $1.16M | $1.57M | $13.8M | $1.98M |
| Inventory | $9.58M | $0.00 | $0.00 | $290K | $330K |
| Total current assets | $115.2M | $102.4M | $68.8M | $118.2M | $156.6M |
| Property, plant and equipment, net | $18.4M | $18.8M | $14.1M | $15.3M | $18.6M |
| Goodwill and intangible assets | $18.4M | $23.6M | $67.3M | $81.4M | $89.8M |
| Long-term investments | $2.51M | $0.00 | $0.00 | $400K | $48.6M |
| Total non-current assets | $41.4M | $42.9M | $82.3M | $97.8M | $203.2M |
| Total assets | $156.6M | $145.3M | $151M | $216M | $359.9M |
| Accounts payable | $12M | $3.53M | $1.73M | $4.07M | $3.11M |
| Short-term debt | $1.14M | $960K | $1.2M | $44.4M | $1.45M |
| Deferred revenue | $520K | $590K | $510K | $30K | $1.49M |
| Total current liabilities | $37.3M | $21.5M | $23M | $78.6M | $34.7M |
| Long-term debt | $97.2M | $4.55M | $5.89M | $6.99M | $188.6M |
| Deferred revenue, non-current | $0.00 | $1.93M | $1.82M | $1.82M | $23M |
| Total non-current liabilities | $98.4M | $85.2M | $9.56M | $11.1M | $217.9M |
| Capital lease obligations | $5.12M | $5.5M | $7.1M | $8.2M | $10.1M |
| Total liabilities | $135.7M | $106.8M | $32.6M | $89.7M | $252.5M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-2.34B | -$-2.09B | -$-1.96B | -$-1.87B | -$-1.92B |
| Accumulated other comprehensive income (loss) | $10K | $10K | -$-1.95M | -$-3.49M | $200K |
| Total equity | $20.9M | $38.5M | $118.5M | $126.3M | $107.4M |
| Total investments | $70.1M | $68.4M | $55.3M | $51.5M | $120.8M |
| Total debt | $98.3M | $5.5M | $7.1M | $51.4M | $190.1M |
| Net debt | $68.1M | -$-24.02M | -$-480K | $46.6M | $153.7M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-250.64M | -$-126.23M | -$-95.9M | $28.3M | -$-92.17M |
| Depreciation and amortization | $3.2M | $4.53M | $6.67M | $10.8M | $13.8M |
| Stock-based compensation | $10.9M | $9.47M | $9.89M | $10.2M | $13.9M |
| Change in working capital | $6.62M | $4.52M | $17.1M | -$-35.7M | -$-800K |
| Accounts receivable | -$-3.2M | $410K | $12.2M | -$-13.51M | -$-6.56M |
| Inventory | -$-9.21M | $0.00 | $0.00 | $2.34M | -$-1.9M |
| Accounts payable | $8.77M | $1.55M | -$-2.42M | $380K | $420K |
| Net cash provided by operating activities | -$-87.83M | -$-68.17M | -$-66.93M | -$-65.05M | -$-55.77M |
| Investments in property, plant and equipment | -$-2M | -$-8.58M | -$-1.54M | -$-4.92M | -$-7.25M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-1.53M | -$-20.71M | -$-3.09M | $226.4M | -$-74.54M |
| Common stock issued | $310K | $31.2M | $72.8M | $0.00 | $121.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $90.1M | $110.6M | $29.6M | -$-155.29M | $121.2M |
| Net change in cash | $720K | $21.7M | -$-40.75M | $5.25M | -$-8.91M |
| Cash at end of period | $30.2M | $29.5M | $7.85M | $48.6M | $43.3M |
| Operating cash flow | -$-87.83M | -$-68.17M | -$-66.93M | -$-65.05M | -$-55.77M |
| Capital expenditure | -$-2M | -$-8.58M | -$-1.54M | -$-4.92M | -$-7.25M |
| Free cash flow | -$-89.83M | -$-76.76M | -$-68.47M | -$-69.97M | -$-63.02M |
Line items
Line items
Line items
About Precigen, Inc.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
- CEO
- Helen Sabzevari
- Employees
- 160
- Beta
- 1.00
Explore
Frequently asked questions
What is the intrinsic value of Precigen, Inc. (PGEN)?
Precigen, Inc. (PGEN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PGEN undervalued?
PGEN trades at a price of $4.21 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.